Abstract # 1042 Assessing the Impact of Technological Advancement on Outcome for Patients with Unresectable Locally Advanced Non-small Cell Lung Cancer (nsclc) Receiving Concomitant Chemoradiotherapy

Presenter: Liao, Zhongxing

< Back to topics

> Cover Page, Authors, Institutions

> Purpose/Objective

> Materials/Methods

> Results/Discussion

> Conclusions

> View tables/images/videos

About the Presenter:
ZHONGXING LIAO, M.D., Associate Professor and Center Medical Director, Department of Radiation Oncology Zhongxing Liao, M.D., Associate Professor and Center Medical Director, Department of Radiation Oncology at The University of Texas M. D. Anderson Cancer Center focuses her clinical efforts on improving the efficacy of chemoradiotherapy for lung and esophageal cancers using molecular targeted therapies. Currently, Dr. Liao is actively involved in translational research using molecular targeting agents. Dr. Liao and a team of researchers have actively explored the use of COX-2 inhibitors in combination with radiotherapy and chemoradiotherapy in patients, completed phase I trial looking at the toxicity of selective COX-2 inhibitor and radiation for Non-small cell lung cancer (NSCLC) patients. She is involved in a phase II study investigating the use of chemoradiation and the COX-2 inhibitor, celeboxcoxib, simultaneously to treat patients with NSCLC. She is also investigating Sorafenib, a multi-targeting agent, and combination with thoracic radiation for NSCLC. This trial is approved by IRB and ready to accrue patients. In addition, Dr. Liao is investigating ways to reduce lung toxicity from chemoradiation. One way to accomplish this goal is to use advance technology such as intensity modulated radiation or proton beam radiation. An Adaptive randomized trial of 3-DCRT versus IMRT for NSCLC, using radiation pneumonitis as endpoint has been approved by IRB and opened for patient accrual. Several translational research projects are build into this trial as well, including PET image for tumor and normal tissue response, serum cytokine studies for pneumonitis, assessment of genetic risk factors for tumor and normal tissue toxicity, and symptom study. The ultimate goal of her research is to tailor treatment to the individual patient. In addition to Dr. Liao’s clinical work and research, she is also actively involved in the development and implementation of a fellowship training program for emerging nations and in the globalization of M. D. Anderson's multidisciplinary approach to cancer management, focusing on Asia. Dr. Liao received her M.D. from Hunan Medical University in China and completed a postdoctoral fellowship in experimental radiation oncology and resident training at M. D. Anderson... She has been recognized as the Best Doctor of America since 2003. She also serves as committee members on number of professional organizations, including American Society for Therapeutic Radiology Oncology (ASTRO), International Society for Study of Lung Cancer, American Radium Society, and American Association for Woman Radiologist.
Contact the presenter at: zliao@mdanderson.org

Authors:
Z. X. Liao*, J. D. Cox*, H. H. Liu*, R. Komaki*, S. L. Tucker*, R. Mohan*, M. Martel*, X. Wei*, P. K. Allen*, H. D. Thames*. , The University of Texas M.D. Anderson Cancer Center, Houston, TX,

Click on images to enlarge (a new pop-up window will open)




E-mail a friend about this abstract:
Enter email address: